With about 217,730 new cases and 32,050 deaths recorded in 2010, prostate cancer is the most common non-dermatologic cancer and the second leading cause of cancer mortality among men in the United States. Particularly in families with a history of early-onset illness, when first-degree relatives run a 2–2.5-fold greater risk of acquiring the disease, genetic elements play a major role in its risk. Son of dads who live longer than 59 months following diagnosis, had a 38% reduced chance of prostate cancer^[1].

Although most occurrences are sporadic, genome-wide research pointing to many risk-associated loci—including 8q24 and 17q—support linkages to ovarian and breast tumors^[2]. Furthermore, two to three percent of cases of prostate cancer are caused by mutations in the BRCA1 and BRCA2 genes; carriers have much higher risks. The Breast Cancer Linkage Consortium initially exposed the relationship between BRCA mutations and prostate cancer by pointing up higher incidence rates in families with a history of ovarian and breast tumors. Found on chromosome 13q12, the gene BRCA2 was discovered in 1995 and codes for a protein essential for DNA repair via homologous recombination^[3]. For DNA damage repair, it helps RAD51 to be localized and activated; BRCA2-deficient cells find it difficult to get RAD51 to the nucleus, therefore compromising DNA repair.

Managing these malignancies, guiding therapy options, especially the use of PARP inhibitors targeting HR-deficient tumors, depends on thorough genetic profiling. Through tailored therapeutic approaches, the changing knowledge of these genetic pathways is essential overall for enhancing patient outcomes. the evolution and effectiveness of PARP inhibitors in treating prostate and ovarian tumors especially. PARP inhibitors including olaparib niraparib and rucaparib excel at treating tumors that carry faults in BRCA1/2 genes but have different ways of working therapeutic breakdown and absorption profiles^[14]. Major drug reactions include stomach issues, low blood cell counts, and fatigue with frequent nausea complaints. Studies demonstrate these inhibitors increase PFS rates in ovarian cancer patients so they receive maintenance therapy recommendations from multiple healthcare settings. Research proves that rucaparib and olaparib PARP inhibitors work best to treat prostate cancer especially for patients with precise genetic changes^[15]. The book demonstrates how HR deficit and BRCA mutation testing help achieve better medical results and explains how PARP inhibitors add to the performance of immune checkpoint inhibitors and other anti-cancer treatments. Our medical field needs to investigate how resistance develops against cancer drugs and how both inherited and damaged DNA impact cancer treatment^[16].

While researchers have investigated the potential of plant extracts like Urtica membranacea, Artemisia monosperma, and Origanum dayi, further research is needed to identify the specific active components responsible for the anticancer effects. These plant extracts are complex mixtures of various phytochemicals and attributing the observed effects to the extract as a whole limits our understanding of the underlying mechanisms^[17]. Isolating and characterizing the individual bioactive molecules within these extracts is crucial. Identifying the specific active compounds is essential for developing targeted therapies. Once the key molecules are identified, their structure-activity relationships can be investigated to optimize their efficacy and minimize potential side effects. This knowledge will pave the way for developing more potent and selective anticancer drugs derived from these natural sources^[18].

PCa stands as the second most common cancer among men worldwide and ranks as the fifth major cause of cancer deaths. The formation of cancer starts with damaged DNA and mutations that can occur either in body cells or throughout the genetic line affect your chances of developing PCa^[19]. When DNA damage response systems fail to safeguard our genome they create cancer especially when BRCA mutations occur. Two genetic mutations called BRCA1 and BRCA2 affect how well HR repairs damage in DNA so the body needs different kinds of repair systems such as BER and NER to fix DNA whenever HR faces challenges^[20]. When cancer cells fail to fix their DNA defects in BRCA-mutated tumors PARP inhibitors create synthetic lethality to destroy them. Medical standards recommend testing at-risk patients while helping doctors identify helpful genetic therapy options by studying their patient's genes^[21]. Different treatment recommendations for different areas, however, show the need of standardized procedures in controlling BRCA-associated prostate cancer.

Due mostly to DNA damage, prostate cancer (PCa) shows notable genomic instability marked by amplifications, deletions, and chromosomal rearrangements^[22]. Specifically BRCa1 and BRCa2, germline mutations in DNA damage response (DDR) genes have been linked to this instability. Nicolosi et al. found that 30.7% of 3,607 men with prostate cancer had germline mutations; other alterations included ATM and PALB2^[23]. With BRCA2 mutations associated to a worse prognosis, advanced metastatic cancer has a greater incidence of BRCA mutations than do original tumors. Damaged p53 and PTEN genes found in advanced tumor stages along with somatic mutations assist health professionals in understanding disease progression patterns^[24]. The BRCA genes support DNA repair and gene activation yet their changes boost the chance of developing cancer. Breast and ovarian cancer mutation families benefit from genetic tests that help determine proper treatments and screening guidelines. Research studies TOPARP and PROFOUND demonstrate that cells with DDR mutations respond best to PARP inhibitors when used to treat advanced prostate cancer that has resisted hormone therapy^[25]. Two additional ways PARP inhibitors develop resistance involve higher drug elimination from cells plus casual reversions in BRCA gene neighborhoods. Our research aims to develop better treatment strategies both by studying BRCA markers beyond DNA-repair differences and by making PARP inhibitors work better for personalized prostate cancer care^[26].

Herbal medicine is becoming more and more important worldwide, especially in underdeveloped nations where it is the main healthcare resource because of the great expenses of modern medications. Treating illnesses, particularly cancer, the main cause of mortality globally, depends mostly on medicinal plants. With one in every 31 women expected to have breast cancer, rates of the illness are especially alarming in South Africa^[27]. Although they have long employed several medicinal plants for cancer therapy, traditional healers in areas like the Eastern Cape still have mostly unrecorded information that is passed down orally^[28]. Usually resulting from DNA mutations brought on by environmental elements, cancer affects 80–90% of instances and has been connected to such causes in study. Developing novel cancer medicines depends on medicinal plants as they provide complex molecular structures impossible to synthesis chemically. With proven great medicinal value, especially in traditional Indian medicine, neem (Azadirachta indica) epitribes this potential^[29]. By causing death in cancer cells, increasing antioxidant activity, and strengthening the immune system, its active compounds—azadirachtins and nimocinol—show anticancer action. Studies show that neem can drastically lower tumor development in animal models and could improve the effectiveness of traditional therapies while lowering negative effects. Joining herbal medicine tradition with modern research methods helps us create better treatments and protect natural medical knowledge to fight more effectively against cancer^[30].

In silico analysis serves today as an essential computational method for studying bioactive compounds as they relate to prostate cancer gene metabolic pathways. The computational method makes use of superior algorithms and molecular modeling methods to estimate the effects of different phytochemicals upon biological pathways and genetic targets^[49]. The research outcome of interaction prediction enables scientists to find therapeutic candidates in a faster and more resource-efficient way when compared to conventional laboratory testing methods. Predictive modeling enables safety and efficacy tests together with bioavailability evaluations during early stages which saves time and reduces costs in the drug discovery pipeline^[50].

Modern bioinformatics and cheminformatics technologies help in silico tools improve their analysis of intricate prostate cancer metabolic pathways. These analytical methods establish simulations that trace how bioactive substances affect specific genetic targets which demonstrates their capacity to control cancer indicators^[54]. The study of phytochemical binding to vital tumor-promoting receptors and enzymes remains possible through molecular docking analysis. Systems biology approaches utilize multiple omics data points including genomics and proteomics together with metabolomics to establish detailed prostate cancer metabolic models which lead to finding new therapeutic targets and biomarkers^[52].

In silico analysis provides a valuable platform for preliminary screening and identification of potential therapeutic compounds. However, the true efficacy and safety of these compounds can only be established through rigorous in vivo studies and clinical trials. In vitro studies, while informative, cannot fully replicate the complex interactions within a living organism. Therefore, translating the promising results observed in silico into clinical settings requires extensive validation in animal models and subsequently in human trials^[51].

Furthermore, clinical validation is essential to assess the long-term effects and potential side effects of these bioactive compounds. While initial studies may demonstrate promising short-term outcomes, long-term evaluation is crucial to determine the sustained impact on cancer control and the potential for adverse effects over extended periods. Clinical trials with diverse patient populations and long-term follow-up are necessary to establish the true clinical utility of these compounds^[52].

The implementation of artificial intelligence alongside machine learning in in silico analysis produces exceptional predictive abilities to discover bioactive compounds with combined effects on prostate cancer treatment. These technologies have the ability to evaluate substantial datasets so they can detect hidden patterns among data points which standard methods would fail to see^[53]. Research teams achieve better candidate selection through the integration of screening outcomes with simulated predictions. Through recent improvements in in silico analysis scientists gain speed in therapeutic agent discovery while creating prospects for personalizing prostate cancer treatment by targeting unique metabolic information and gene expressions^[54].

The research studies the combination between in-silico bioactive compound analysis with genetic metabolic interactions that affect prostate cancer development. The frequency of prostate cancer occurs as the main malignancy affecting males because BRCA1 and BRCA2 mutations create genetic damage to DNA repair systems while increasing risk for aggressive disease forms. BRCA2 mutations raise PCa risk four times higher than other mutations do. The research demonstrates that mutations in tumors lead to positive reactions with DNA-damaging medications mainly PARP inhibitors through dysfunctional DNA repair system exploitation. This paper explores the combination opportunities between traditional herbal medicines and modern scientific approaches while studying anticancer properties of Neem and Giloy among other plants. Researchers use in-silico computational approaches to discover therapeutic compounds together with their genetic target bonds which enables creation of patient-specific treatment approaches. The inclusion of research-based natural compounds into clinical procedures would improve PCa treatment results yet ongoing studies must examine their actions in modern healthcare settings.